[Expert recommendations on the use of teduglutide in pediatric patients with short bowel syndrome].

{"article_title":"[Expert recommendations on the use of teduglutide in pediatric patients with short bowel syndrome].","author":"Martinez MI, Balacco M, Busoni V, Fernandez A, Rumbo C","journal_title":"Medicina","issn":"1669-9106","isbn":"","publication_date":"2021 Aug","volume":"83","issue":"1","first_page":"114","page_count":"","accession_number":"36774605","doi":"","publisher":"Fundacion Revista Medicina (Buenos Aires)","doctype":"English Abstract","subjects":"Short Bowel Syndrome drug therapy; Glucagon-Like Peptides analogs & derivatives; Child; Humans; Glucagon-Like Peptide 2 adverse effects; Peptides therapeutic use","interest_area":["Pediatric Medicine"," Gastroenterology"," Internal\/Family Medicine"],"abstract":"Short bowel syndrome is a low-incidence disorder among pediatric patients, but it is associated with high morbidity and mortality rates. Management of these patients by an interdisciplinary team of experts focused on intestinal rehabilitation improves short- and long-term outcomes. Available resources for treatment include teduglutide, a glucagon-like peptide type 2 (GLP-2) analog made by recombinant techniques. Considering the available evidence and the authors' experience, Delphi-based recommendations for the use of teduglutide are suggested for healthcare professionals who treat pediatric patients with short bowel syndrome, as well as for health authorities.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=36774605&authtype=shib&custid=ns346513&group=main&profile=eds"}